Skip to content

Insider · CIK 0001707685

Christine Marie Utter

officer

Files at PTCT (PTC THERAPEUTICS, INC.). First filing Dec 4, 2024, latest Dec 4, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $922k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

PTCT: PTC THERAPEUTICS, INC.

PTCTOct 9, 2026 · close 64.70

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
29Weak
PTCTsell 410b5-1
PTC THERAPEUTICS, INC.
$922k
17,800 shares
-32%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
MOption exercise
Common Stock10b5-1
+3,105$51.00$158k55,533Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
SOpen-market sale
Common Stock10b5-1
-2,497$51.34$128k53,036Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
SOpen-market sale
Common Stock10b5-1
-608$52.24$32k52,428Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
MOption exercise
Common Stock10b5-1
+14,695$51.00$749k67,123Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
SOpen-market sale
Common Stock10b5-1
-9,919$51.53$511k57,204Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
SOpen-market sale
Common Stock10b5-1
-4,776$52.45$251k52,428Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-3,105$0.00$014,695Dec 4, 2024
Dec 2, 2024PTCT
PTC THERAPEUTICS, INC.
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-14,695$0.00$00Dec 4, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.